Recce Pharmaceuticals Ltd. (R9Q) Price & Analysis

1 Followers

R9Q Stock Chart & Stats

€0.20

€0.00(0.00%)

At close: Jul 24 4:00 PM EDT

€0.20

€0.00(0.00%)

Day’s Range― - ―

52-Week Range€0.15 - €0.45

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€64.16M

Enterprise Value€124.87M

Total Cash (Recent Filing)€2.69M

Total Debt (Recent Filing)€10.44M

Price to Earnings (P/E)―

Beta1.16

Next Earnings

Mar 01, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.05

Shares Outstanding305,770,080

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.18

Price to Book (P/B)-7.00

Price to Sales (P/S)0.00

P/FCF Ratio-11.77

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.05

Revenue Forecast (FY)€5.53M

Bulls Say, Bears Say

Bulls Say

Anti-infective PipelineThe pipeline addresses bacterial infections and drug-resistant pathogens, an enduring medical need identified in the company description. If clinical development succeeds, these candidates could support a differentiated position in areas where existing treatments remain inadequate.

Clinical Development FocusClinical evaluation across infected wounds and serious bacterial infections gives the company defined therapeutic applications rather than an undirected research program. Progress in these indications could broaden the eventual commercial opportunity and improve the pipeline’s strategic relevance.

Recent Cash-flow ImprovementCash flow improved modestly in 2026 compared with the notably weaker 2025 result, indicating some near-term stabilization in cash consumption. Although burn remains substantial, sustained improvement would extend financial runway and reduce pressure on future funding decisions.

Bears Say

Zero Revenue And Persistent LossesThe 2026 collapse to zero revenue, combined with negative gross profit and continuing operating and net losses, shows that the company has not established a reliable commercial earnings base. This weakens internal funding capacity and leaves future value dependent on development progress.

Negative Equity And Higher DebtNegative equity alongside materially higher debt indicates a weakened capital structure and reduced financial flexibility. The company may face greater dilution or refinancing pressure, limiting its ability to fund clinical development and absorb setbacks without additional capital.

Persistent Cash BurnConsistently negative operating and free cash flow demonstrate that the business is consuming cash rather than self-funding operations. Continued reliance on external funding can constrain investment choices, increase financing risk, and make execution more sensitive to capital availability.

Recce Pharmaceuticals Ltd. News

Recce and Arrotex Strike Exclusive Deal for Diabetic Foot Infection Gel

Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) has issued an announcement. Recce Pharmaceuticals and Arrotex Pharmaceuticals have signed an...

5d ago

Recce Faces Key DMC Review as Phase 3 Diabetic Foot Gel Trial Shows Strong Signals

An announcement from Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) is now available. Recce Pharmaceuticals reported that blinded data...

7d ago

Recce Pharmaceuticals Sets 2026 AGM as Synthetic Anti-Infective Pipeline Gains Recognition

Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) just unveiled an announcement. Recce Pharmaceuticals has dispatched materials for its 2026...

20d ago

Recce Pharmaceuticals Reports Lapse of Conditional Options

Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) has shared an announcement. Recce Pharmaceuticals has notified the market of the...

26d ago

Recce Pharmaceuticals faces shareholder push for governance changes and board shake-up

Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) has provided an update. Recce Pharmaceuticals has received a shareholder notice under...

28d ago

Recce Sets 2026 AGM Date as It Advances Synthetic Anti-Infective Pipeline

The latest update is out from Recce Pharmaceuticals Ltd. ( ($AU:RCE) ). Recce Pharmaceuticals has scheduled its 2026...

1M ago

Recce Investors Reject Option Issues and Placement Ratification at General Meeting

The latest update is out from Recce Pharmaceuticals Ltd. ( ($AU:RCE) ). Recce Pharmaceuticals reported the results of...

2M ago

Recce Pharmaceuticals Issues Investor Presentation with Extensive Legal Disclaimers

The latest announcement is out from Recce Pharmaceuticals Ltd. ( ($AU:RCE) ). Recce Pharmaceuticals has released a general...

2M ago

Recce Pharmaceuticals Files ASX Corporate Governance Statement and Appendix 4G

Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) has issued an announcement. Recce Pharmaceuticals has lodged its corporate governance statement...

2M ago

Recce Pharmaceuticals Narrows Loss as Global Anti-Infective Programs Advance

Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) just unveiled an update. Recce Pharmaceuticals reported a narrower net loss for...

2M ago

R9Q FAQ

What was Recce Pharmaceuticals Ltd.’s price range in the past 12 months?

Recce Pharmaceuticals Ltd. lowest stock price was €0.15 and its highest was €0.45 in the past 12 months.

What is Recce Pharmaceuticals Ltd.’s market cap?

Recce Pharmaceuticals Ltd.’s market cap is €64.16M.

When is Recce Pharmaceuticals Ltd.’s upcoming earnings report date?

Recce Pharmaceuticals Ltd.’s upcoming earnings report date is Mar 01, 2027 which is in 125 days.

How were Recce Pharmaceuticals Ltd.’s earnings last quarter?

Recce Pharmaceuticals Ltd. released its earnings results on Aug 31, 2026. The company reported €0.004 earnings per share for the quarter.

Is Recce Pharmaceuticals Ltd. overvalued?

According to Wall Street analysts Recce Pharmaceuticals Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Recce Pharmaceuticals Ltd. pay dividends?

Recce Pharmaceuticals Ltd. does not currently pay dividends.

What is Recce Pharmaceuticals Ltd.’s EPS estimate?

Recce Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Recce Pharmaceuticals Ltd. have?

Recce Pharmaceuticals Ltd. has 305,770,080 shares outstanding.

What happened to Recce Pharmaceuticals Ltd.’s price movement after its last earnings report?

Recce Pharmaceuticals Ltd. reported an EPS of €0.004 in its last earnings report. Following the earnings report the stock price went down -1.015%.

Which hedge fund is a major shareholder of Recce Pharmaceuticals Ltd.?

Currently, no hedge funds are holding shares in DE:R9Q

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Recce Pharmaceuticals Ltd. Stock Smart Score

Outperform

Fundamentals

Return on Equity

84.67%

Trailing 12-Months

Asset Growth

-31.31%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Recce Pharmaceuticals Ltd.

Recce Pharmaceuticals Ltd operates as a biotechnology enterprise, concentrating on the research, advancement, and market introduction of synthetic anti-infective treatments across Australia, the United States, and the United Kingdom. The company's foremost developmental drug, RECCE 327, is intended to address blood infections and sepsis caused by E. coli and S. aureus bacteria, including their antibiotic-resistant variants. Additionally, Recce is progressing RECCE 529, a synthetic anti-infective targeting viral illnesses, and RECCE 435, another synthetic polymer anti-infective. Founded in 2007, the firm, which was initially named Recce Limited, officially became Recce Pharmaceuticals Ltd in November 2017. Its corporate headquarters are situated in Sydney, Australia.